Cell Reports MedicinePub Date : 2024-12-17Epub Date: 2024-12-09DOI: 10.1016/j.xcrm.2024.101853
En Ying Tan, Mark D Muthiah, Arun J Sanyal
{"title":"Metabolomics at the cutting edge of risk prediction of MASLD.","authors":"En Ying Tan, Mark D Muthiah, Arun J Sanyal","doi":"10.1016/j.xcrm.2024.101853","DOIUrl":"10.1016/j.xcrm.2024.101853","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major public health threat globally. Management of patients afflicted with MASLD and research in this domain are limited by the lack of robust well-established non-invasive biomarkers for diagnosis, prognostication, and monitoring. The circulating metabolome reflects both the systemic metabo-inflammatory milieu and changes in the liver in affected individuals. In this review we summarize the available literature on changes in the different components of the metabolome in MASLD with a focus on changes that are linked to the presence of underlying steatohepatitis, severity of disease activity, and fibrosis stage. We further summarize the existing literature around biomarker panels that are derived from interrogation of the metabolome. Their relevance to disease biology and utility in practice are also discussed. We further highlight potential direction for future studies particularly to ensure they are fit for purpose and suitable for widespread use.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101853"},"PeriodicalIF":11.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-12-17Epub Date: 2024-12-03DOI: 10.1016/j.xcrm.2024.101842
Hajime Yamazaki, Samantha A Streicher, Lang Wu, Shunichi Fukuhara, Róbert Wagner, Martin Heni, Steven R Grossman, Heinz-Josef Lenz, Veronica Wendy Setiawan, Loïc Le Marchand, Brian Z Huang
{"title":"Evidence for a causal link between intra-pancreatic fat deposition and pancreatic cancer: A prospective cohort and Mendelian randomization study.","authors":"Hajime Yamazaki, Samantha A Streicher, Lang Wu, Shunichi Fukuhara, Róbert Wagner, Martin Heni, Steven R Grossman, Heinz-Josef Lenz, Veronica Wendy Setiawan, Loïc Le Marchand, Brian Z Huang","doi":"10.1016/j.xcrm.2024.101842","DOIUrl":"10.1016/j.xcrm.2024.101842","url":null,"abstract":"","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101842"},"PeriodicalIF":11.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-12-17Epub Date: 2024-12-04DOI: 10.1016/j.xcrm.2024.101846
Laurenz T Ursch, Jule S Müschen, Julia Ritter, Julia Klermund, Bettina E Bernard, Saskia Kolb, Linda Warmuth, Geoffroy Andrieux, Gregor Miller, Marina Jiménez-Muñoz, Fabian J Theis, Melanie Boerries, Dirk H Busch, Toni Cathomen, Kathrin Schumann
{"title":"Modulation of TCR stimulation and pifithrin-α improve the genomic safety profile of CRISPR-engineered human T cells.","authors":"Laurenz T Ursch, Jule S Müschen, Julia Ritter, Julia Klermund, Bettina E Bernard, Saskia Kolb, Linda Warmuth, Geoffroy Andrieux, Gregor Miller, Marina Jiménez-Muñoz, Fabian J Theis, Melanie Boerries, Dirk H Busch, Toni Cathomen, Kathrin Schumann","doi":"10.1016/j.xcrm.2024.101846","DOIUrl":"10.1016/j.xcrm.2024.101846","url":null,"abstract":"<p><p>CRISPR-engineered chimeric antigen receptor (CAR) T cells are at the forefront of novel cancer treatments. However, several reports describe the occurrence of CRISPR-induced chromosomal aberrations. So far, measures to increase the genomic safety of T cell products focused mainly on the components of the CRISPR-Cas9 system and less on T cell-intrinsic features, such as their massive expansion after T cell receptor (TCR) stimulation. Here, we describe driving forces of indel formation in primary human T cells. Increased T cell activation and proliferation speed correlate with larger deletions. Editing of non-activated T cells reduces the risk of large deletions with the downside of reduced knockout efficiencies. Alternatively, the addition of the small-molecule pifithrin-α limits large deletions, chromosomal translocations, and aneuploidy in a p53-independent manner while maintaining the functionality of CRISPR-engineered T cells, including CAR T cells. Controlling T cell activation and pifithrin-α treatment are easily implementable strategies to improve the genomic integrity of CRISPR-engineered T cells.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101846"},"PeriodicalIF":11.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-12-17Epub Date: 2024-12-05DOI: 10.1016/j.xcrm.2024.101836
Maartje Kristensen, Wouter A A de Steenhuijsen Piters, Joanne Wildenbeest, Marlies A van Houten, Roy P Zuurbier, Raiza Hasrat, Kayleigh Arp, Mei Ling J N Chu, Marie Billard, Terho Heikkinen, Steve Cunningham, Matthew Snape, Simon B Drysdale, Ryan S Thwaites, Federico Martinon-Torres, Andrew J Pollard, Peter J M Openshaw, Jeroen Aerssen, Justyna Binkowska, Louis Bont, Debby Bogaert
{"title":"The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children.","authors":"Maartje Kristensen, Wouter A A de Steenhuijsen Piters, Joanne Wildenbeest, Marlies A van Houten, Roy P Zuurbier, Raiza Hasrat, Kayleigh Arp, Mei Ling J N Chu, Marie Billard, Terho Heikkinen, Steve Cunningham, Matthew Snape, Simon B Drysdale, Ryan S Thwaites, Federico Martinon-Torres, Andrew J Pollard, Peter J M Openshaw, Jeroen Aerssen, Justyna Binkowska, Louis Bont, Debby Bogaert","doi":"10.1016/j.xcrm.2024.101836","DOIUrl":"10.1016/j.xcrm.2024.101836","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is the leading cause of infant respiratory infections and hospitalizations. To investigate the relationship between the respiratory microbiome and RSV infection, we sequence nasopharyngeal samples from a birth cohort and a pediatric case-control study (Respiratory Syncytial virus Consortium in Europe [RESCEU]). 1,537 samples are collected shortly after birth (\"baseline\"), during RSV infection and convalescence, and from healthy controls. We find a modest association between baseline microbiota and the severity of consecutive RSV infections. The respiratory microbiota during infection clearly differs between infants with RSV and controls. Haemophilus, Streptococcus, and Moraxella abundance are associated with severe disease and persistence of symptoms, whereas stepwise increasing abundance of Dolosigranulum and Corynebacterium is associated with milder disease and health. We conclude that the neonatal respiratory microbiota is only modestly associated with RSV severity during the first year of life. However, the respiratory microbiota at the time of infection is strongly associated with disease severity and residual symptoms.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101836"},"PeriodicalIF":11.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-12-17Epub Date: 2024-11-29DOI: 10.1016/j.xcrm.2024.101837
Tao Zhang, Pengyu Wang, Hailing Zhou, Bingyan Wei, Yanling Zhao, Jiahui Li, Min Zhang, Wenjuan Wu, Lefu Lan, Jianhua Gan, Cai-Guang Yang
{"title":"Structure-guided development of selective caseinolytic protease P agonists as antistaphylococcal agents.","authors":"Tao Zhang, Pengyu Wang, Hailing Zhou, Bingyan Wei, Yanling Zhao, Jiahui Li, Min Zhang, Wenjuan Wu, Lefu Lan, Jianhua Gan, Cai-Guang Yang","doi":"10.1016/j.xcrm.2024.101837","DOIUrl":"10.1016/j.xcrm.2024.101837","url":null,"abstract":"<p><p>Methicillin-resistant Staphylococcus aureus is a ubiquitous pathogen, posing a serious threat to human health worldwide. Thus, there is a high demand for antibiotics with distinct targets. Caseinolytic protease P (ClpP) is a promising target for combating staphylococcal infections; however, selectively activating S. aureus ClpP (SaClpP) rather than Homo sapiens ClpP (HsClpP) remains challenging. Herein, we rationally design and identify ZG297 by structure-based strategy. It binds and activates SaClpP instead of HsClpP. This is due to differentiated ligand binding attributed to crossed \"tyrosine/histidine\" amino acid pairs. ZG297 substantially inhibits the growth of a broad panel of S. aureus strains in vitro, outperforming the selective (R)-ZG197 agonist. ZG297 also functions as a potent antibiotic against multidrug-resistant S. aureus infections in Galleria mellonella larvae, zebrafish, murine skin, and thigh infection models. Collectively, we demonstrate that ZG297 is a safer and more potent antistaphylococcal agent than acyldepsipeptide 4 and (R)-ZG197.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101837"},"PeriodicalIF":11.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-12-17Epub Date: 2024-11-29DOI: 10.1016/j.xcrm.2024.101833
Yuchen Zhang, Qihua Zou, Baitian Zhao, Ning Su, Zhihua Li, Xicheng Wang, Panpan Liu, Xiaopeng Tian, Xiaojie Fang, Jun Cai, Lirong Li, Yingxian Liu, Yi Xia, Qingqing Cai
{"title":"Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL).","authors":"Yuchen Zhang, Qihua Zou, Baitian Zhao, Ning Su, Zhihua Li, Xicheng Wang, Panpan Liu, Xiaopeng Tian, Xiaojie Fang, Jun Cai, Lirong Li, Yingxian Liu, Yi Xia, Qingqing Cai","doi":"10.1016/j.xcrm.2024.101833","DOIUrl":"10.1016/j.xcrm.2024.101833","url":null,"abstract":"<p><p>Treatment options for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) after failure of platinum-based therapy are limited. In this phase 2 trial, 40 patients with RM-NPC who failed platinum-based chemotherapy receive toripalimab plus anlotinib regimen. The objective response rate is 37.5%, and the disease control rate is 85.0%. With a median follow-up of 17.4 months, the median progression-free survival (PFS) is 9.5 months and 1-year overall survival rate is 73.3%. The most common treatment-related grade 3-4 adverse events are hand-foot syndrome (22.5%) and oral mucositis (17.5%). Analyses of plasma circulating tumor DNA (ctDNA) demonstrate that the blood tumor mutation burden at cycle 1/2 is associated with response and PFS, and disease progression indicated by ctDNA precedes radiological progression by a median of 2.3 months. In conclusion, toripalimab plus anlotinib is well tolerated and shows promising efficacy in patients with RM-NPC, and ctDNA could be a potential predictive biomarker. The trial is registered at ClinicalTrials.gov (NCT04996758).</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101833"},"PeriodicalIF":11.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-12-17Epub Date: 2024-12-02DOI: 10.1016/j.xcrm.2024.101841
Joel R Martin, Daniel Cleary, Mickey E Abraham, Michelle Mendoza, Betty Cabrera, Catriona Jamieson, Martin Marsala, Joseph D Ciacci
{"title":"Long-term clinical and safety outcomes from a single-site phase 1 study of neural stem cell transplantation for chronic thoracic spinal cord injury.","authors":"Joel R Martin, Daniel Cleary, Mickey E Abraham, Michelle Mendoza, Betty Cabrera, Catriona Jamieson, Martin Marsala, Joseph D Ciacci","doi":"10.1016/j.xcrm.2024.101841","DOIUrl":"10.1016/j.xcrm.2024.101841","url":null,"abstract":"<p><p>We report the long-term results for a phase 1 study of neural stem cell transplantation for chronic spinal cord injury. The trial was registered on ClinicalTrials.gov as NCT01772810. The primary outcome of the trial was to test the feasibility and safety of human spinal cord-derived neural stem cell (NSI-566) transplantation for the treatment of chronic spinal cord injury in four subjects with thoracic two to thoracic twelve spinal cord injury. Here, we report that all four subjects tolerated the stem cell implantation procedure well, and two subjects had durable electromyography-quantifiable evidence of neurological improvement as well as increased neurological motor and sensory scores at five years post-transplantation.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101841"},"PeriodicalIF":11.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy.","authors":"Min Shi, Yingxi Yang, Na Huang, Dongqiang Zeng, Zongchao Mo, Jiao Wang, Xiaomeng Zhang, Ran Liu, Chunlin Wang, Xiaoxiang Rong, Zhenzhen Wu, Qiong Huang, Haixia Shang, Jihong Tang, Zhaojun Wang, Jianan Cai, Genjie Huang, Yijin Guan, Jian Guo, Quanhua Mu, Jiguang Wang, Wangjun Liao","doi":"10.1016/j.xcrm.2024.101838","DOIUrl":"10.1016/j.xcrm.2024.101838","url":null,"abstract":"<p><p>Drug resistance limits the efficacy of chemotherapy for colorectal cancer liver metastasis (CRLM). However, the evolution of CRLM during drug treatment remains poorly elucidated. Multi-omics and treatment response data from 115 samples of 49 patients with CRLM undergoing bevacizumab (BVZ)-based chemotherapy show little difference in genomic alterations in 92% of cases, while remarkable differences are observed at the transcriptomic level. By decoupling intrinsic and acquired resistance, we find that hepatocyte and myeloid cell infiltration contribute to 38.5% and 23.1% of acquired resistance, respectively. Importantly, SMAD4 mutations and chr20q copy-number gain are associated with intrinsic chemoresistance. Gene interference experiments suggest that SMAD4<sup>R361</sup><sup>H/C</sup> mutations confer BVZ and 5-fluorouracil (5-FU) resistance through STAT3 signaling. Notably, supplementing BVZ and 5-FU with the STAT3 inhibitor GB201 restores therapeutic efficacy in SMAD4<sup>R361</sup><sup>H/C</sup> cancer cells. Our study uncovers the evolutionary dynamics of CRLM and its microenvironment during treatment and offers strategies to overcome drug resistance.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101838"},"PeriodicalIF":11.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effect of remote ischemic preconditioning on cerebral circulation time in severe carotid artery stenosis: Results from the RIC-CCT trial.","authors":"Quan-Ying Liu, Yu Cui, Wei Li, Jing Qiu, Thanh N Nguyen, Hui-Sheng Chen","doi":"10.1016/j.xcrm.2024.101796","DOIUrl":"10.1016/j.xcrm.2024.101796","url":null,"abstract":"<p><p>In patients with severe internal carotid artery stenosis (sICAS), cerebral circulation time (CCT) is associated with cerebral hyperperfusion syndrome. This study aims to investigate the effect of remote ischemic preconditioning (RIC) on CCT in patients with sICAS. Patients are randomly assigned to the RIC group (RIC twice daily, for 2-4 days before carotid artery stenting [CAS] as an adjunct to standard medical therapy) and the control group. The results show that RIC produces a significant decrease in CCT of the stenosis side (sCCT) from baseline to pre-CAS, and the occurrence of contrast staining on brain computed tomography (CT) is lower in RIC versus control group after CAS. In addition, significant changes in some serum biomarkers suggest that anti-neuroinflammation, anti-oxidative stress, protecting endothelial injury, and improving cerebral autoregulation may be associated with the effect of RIC. These findings provide supporting evidence that RIC can modulate cerebral circulation in patients with sICAS. This study was registered at ClinicalTrials.gov (NCT05451030).</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101796"},"PeriodicalIF":11.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11604480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-11-19Epub Date: 2024-11-12DOI: 10.1016/j.xcrm.2024.101824
Yiqian Gu, Ann Ly, Sara Rodriguez, Hanwei Zhang, Jiyoon Kim, Zhiyuan Mao, Ankush Sachdeva, Nazy Zomorodian, Matteo Pellegrini, Gang Li, Sandy Liu, Alexandra Drakaki, Matthew B Rettig, Arnold I Chin
{"title":"PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers.","authors":"Yiqian Gu, Ann Ly, Sara Rodriguez, Hanwei Zhang, Jiyoon Kim, Zhiyuan Mao, Ankush Sachdeva, Nazy Zomorodian, Matteo Pellegrini, Gang Li, Sandy Liu, Alexandra Drakaki, Matthew B Rettig, Arnold I Chin","doi":"10.1016/j.xcrm.2024.101824","DOIUrl":"10.1016/j.xcrm.2024.101824","url":null,"abstract":"<p><p>Small cell neuroendocrine cancers share biologic similarities across tissue types, including transient response to platinum-based chemotherapy with rapid progression of disease. We report a phase 1b study of pembrolizumab in combination with platinum-based chemotherapy in 15 patients with stage III-IV small cell bladder (cohort 1) or small cell/neuroendocrine prostate cancers (cohort 2). Overall response rate (ORR) is 43% with two-year overall survival (OS) rate of 86% (95% confidence interval [CI]: 0.63, 1.00) for cohort 1 and 57% (95% CI: 0.30, 1.00) for cohort 2. Treatment is tolerated well with grade 3 or higher adverse events occurring in 40% of patients with no deaths or treatment cessation secondary to toxicity. Single-cell and T cell receptor sequencing of serial peripheral blood samples reveals clonal expansion of diverse T cell repertoire correlating with progression-free survival. Our results demonstrate promising efficacy and safety of this treatment combination and support future investigation of this biomarker. This study was registered at ClinicalTrials.gov (NCT03582475).</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"101824"},"PeriodicalIF":11.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11604497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
